Skip to content
Home/Companies/Pharma/Crossject

Crossject

Pharma·France·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Crossject?

Crossject is currently owned by VATEL CAPITAL through Vatel Flexible (2021 vintage), since 2025.

Hand-verified · updated 2026-04-21

VATEL CAPITAL
Investor
VATEL CAPITAL
Vatel Flexible · 2021 · Evergreen

Key facts

HQFrance
SectorPharma

More from Vatel Flexible

Other portfolio companies in the same fund.

Enogia
Active
EnergyFrance· 2025
Entech
Entech
Active
EnergyFrance· 2025
Haffner Energy
Haffner Energy
Active
EnergyFrance· 2025
Hoffmann Green Cement
Hoffmann Green Cement
Active
ClimateTechFrance· 2025
Iznes
Active
FintechFrance· 2025
Largo
Active
E-commerceFrance· 2025

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track Crossject

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Crossject?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Crossject.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue